Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Ian Wilders, managing director of Labo’Life, a Spanish micro-immunotherapy specialist, discusses the company’s history and the importance of regulatory reform in giving them greater market access and shifting the mindset…
José Luis Martin, director general of HC Clover, a Spanish manufacturer of soft gelatin capsules, highlights how they adapt their services to clients as well as their strategy for rapid…
Aurora Berra, general manager of Sobi Spain and Portugal, highlights her key priorities and the opportunities and challenges inherent in the fragmented Spanish healthcare system. Berra gives insight into the…
Silvia Casellas, CEO of Anagram, a Spanish CRO, discusses the challenges of the consolidation process the company has gone in recent years, the reasons for the boom in Spain’s clinical…
Teresa Chavarria Gimenez, director general of planning, research and training at the Ministry of Health of the Community of Madrid, highlights her role and the BioMad initiative as they look…
Rafael Mella, general manager of Nordic Pharma Spain & Portugal, highlights the steps he has taken to set-up the foundations for the company in the Spanish market and how he…
Alfonso García Cañamaque, CEO of León Research, gives an overview of the Spanish clinical research ecosystem and the challenges facing CROs. Also, he explains the differentiating factor of the company…
Albert Barberá, director general of research and innovation in health for the Government of Catalonia, highlights his top priorities to facilitate the growth of the Catalan innovation scene and how…
Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life…
Cristina Garmendia, president of the Cotec Foundation, gives an overview of the innovation landscape in Spain and the steps needed to see this grow in the future. Furthermore, she gives…
Javier Urzay, deputy director of Farmaindustria, gives an overview of the growth of the pharmaceutical sector in Spain and the challenges to find a balance between rewarding innovation and sustainability.…
Angeles Delgado, president of Spain and Portugal for Fujitsu, a globally leading Japanese ICT company, discusses the long history of the company’s presence in Spain and within its healthcare system.…
See our Cookie Privacy Policy Here
